Investor Presentation

ic/vancecl Enzymes WhoreENZYMEisLife AdvancedEnzymeTechnologiesLtd. CIN:L24200MH1989PLC051018 SunMagnetica,Awing,5thFloor,LICServiceRoad,Louiswadi,Thane(W)-400604,India Tel:+91-22-41703200,Fax:+91-22-25835159 Email:info@advancedenzymes. com, www.advancedenzymes. October 31, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Subject: Earnings Presentation Ref: ISIN: INE837H01020 Dear Sir/Madam, Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the Earnings Presentation for the quarter and half year ended September 30, 2026. This is for your information and for public at large. Thanking you, Yours faithfully, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head – Legal Encl.: As above R BUSIN Factory:PlotNo.A-61/62,MIDCMalegaon,Tal.Sinnar,Dist.Nashik-422113.Maharashtra.India.Tel.:+91-9970100750/+91-2551-230044,Fax:+91-2551-230816 Kfranced enzymes WhereENZYMEisLife Advanced Enzyme Technologies Limited Earnings Presentation October 2026 Safe Harbour Statement This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words “believe,”“expect,”“anticipate,” “intend,”“estimate,”“outlook,” “will,”“may,”“continue,”“should”and similar expressions identify forward-looking statements. Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company’s markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and maybe beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements. The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations. By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions. EarningsPresentation | October 2026 Advanced enzymes WhereENZYMEisLife Performance Business 01 02 Summary | Q2 FY27 | Page 04 Performance | Page 07 Geographical Result 03 04 Performance | Page 11 Summary | Q2 FY27 | Page 12 Unique Focus Area 05 06 Investment Case | Page 26 Going Ahead | Page 29 TABLE OF Shareholders’ Information | Page 30 CONTENTS EarningsPresentation | October 2026 Results Summary – Q2 FY27 (Consolidated) Y-o-Y /advancedenzymes WhereENZYMEisLife Revenue (`mn) EBITDA (`mn) PAT (`mn) 2,145 721 512 1,845 601 447 16 4 20 4 14 % % % Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Revenue grew by 16% on y-o-y basis to EBITDA grew by 20% to ₹ 721 million in the Q2 PAT increased to ₹ 512 million in the Q2 FY27 EBITDA margin and PAT margin during ₹ 2,145 million in the Q2 FY27 from ₹ 1,845 FY27 as against ₹ 601 million in Q2 FY26 on y- from ₹ 447 million in the Q2 FY26, an uptick Q2 FY27 stands at 34% and 24% million in the Q2 FY26 o-y basis of 14% on y-o-y basis respectively Notes: 1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return EarningsPresentation | October 2026 Results Summary – Q2 FY27 (Consolidated) Q-o-Q /advancedenzymes WhereENZYMEisLife Revenue (` mn) EBITDA (`mn) PAT (`mn) 2,145 721 512 1,917 * 12 36 529 33 386 % % % i i i Q1 FY27 Q2 FY27 Q1 FY27 Q2 FY27 Q1 FY27 Q2 FY27 Revenue grew by 12% on q-o-q basis to EBITDA grew by 36% to ₹ 721 million in the Q2 PAT increased to ₹ 512 million in the Q2 ₹ 2,145 million in the Q2 FY27 from ₹ 1,917 FY27 as against ₹ 529 million in Q1 FY27 on FY27 from ₹ 386 million in the Q1 FY27, a million in the Q1 FY27 sequential basis growth of 33% on q-o-q basis Notes: 1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return EarningsPresentation | October 2026 Results Summary – H1 FY27 (Consolidated) YTD /advancedenzymes WhereENZYMEisLife Revenue (` mn) EBITDA (`mn) PAT (`mn) 4,062 1,250 3,704 1,165 852 897 10 4 7 4 5 % % % H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 Revenue grew by 10% on YTD basis to ₹ 4,062 EBITDA grew by 7% to ₹ 1,250 million in the H1 PAT increased to ₹ 897 million in the H1 FY27 EBITDA margin and PAT margin during H1 million in the H1 FY27 from ₹ 3,704 million in FY27 as against ₹ 1,165 million in H1 FY26 on from ₹ 852 million in the H1 FY26, an uptick FY27 stands at 31% and 22% respectively the H1 FY26 YTD basis of 5% on YTD basis Notes: 1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return EarningsPresentation | October 2026 Human Nutrition /ancerienzymes WhoreENZYMEisLife, (₹in Million) 2^ 'j/ Q2FY27 Q2 FY26 H1FY27 H1 FY26 60% 60% +6% +0.4% of Sales 1,285 1,212 2,443 2,434 of Sales Commentary: 1,221 1,212 1,281 1,285 • The human nutrition segment contributed around 60% during the 1,158 quarter to the total revenue from operations 992 1,018 1,031 • This segment grew by 6% during the quarter from ₹ 1,212 million in Q2 FY26to ₹ 1,285 million in Q2 FY27 and it grew by 11% on sequential basis Commentary: • The human nutrition segment contributed around 60% during the first half to the total revenue from operations • This segment remained flat during the first half from ₹ 2,434 million in H1 FY26 to ₹ 2,443 million in H1 FY27 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Notes: All the decimals are rounded off to their relevant nearest number EarningsPresentation | October 2026 7 Animal Nutrition dvencedenzymes WhereENZYMEisLife (₹in Million) Q2FY27 Q2 FY26 H1FY27 H1 FY26 12% 13% +37% +14% of Sales 265 193 517 452 of Sales (cid:127) (cid:127) V Commentary: h260 ill 265 • The animal nutrition segment contributed around 12% during the 244 250 252 quarter to the total revenue from operations HI209 % • This segment grew by 37% during the quarter from ₹ 193 million in 197 193 - 181 Q2 FY26to ₹ 265 million in Q2 FY27 whereas it grew by 5% on £s-A I sequential basis Commentary: • The animal nutrition segment contributed around 13% during the quarter to the total revenue from operations • This segment grew by 14% on YTD basis to ₹ 517 million in H1 FY27 [Showing first 8,000 characters — download PDF for full document]